P < 0.0001

TD, toxic death; SFGM, French national registry.

TD, toxic death; SFGM, French national registry.

Figure 75.2 Overall survival of transplanted patients with relapsed or primary refractory disease

at time of study enrollment), group A, were treated exactly the same as in the second-generation program; in that study FFTF was 80%. Patients with two risk factors, group B, received one dose of standard-dose ICE followed by a dose of augmented ICE second-line therapy as well as a more dose-intense transplant-conditioning regimen. Finally, patients with all three risk factors, group C, received a completely different regimen. Cytoreduction was done with transplant doses of ICE followed by stem cell support, which was followed by a second autotransplant. This three-arm study, however, uses one universal theme: patients must have chemosensitive disease to their "ICE" therapy—group A to standard doses of ICE, group B to augmented ICE, and group C to transplant doses of ICE. The median follow-up of the patients is now 30 months and patients with multiple risk factors have improved FFTF as compared to our previous report (unpublished data).

0 0

Post a comment